Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing.

In the development of therapies, the company relies on CRISPR and prime editing, whereby single nucleotides in a DNA sequence can be modified without cutting the DNA, theoretically reducing the likelihood of off-target effects compared to previous CRISPR-based methods[vague].

Co-founders include David R. Liu and Feng Zhang.

[4] Prior to its IPO, the company raised nearly $1 billion in venture capital from investors.

[5] In January 2022, Pfizer and Beam Therapeutics announced a collaboration to develop therapies for rare diseases using CRISPR.